related to our own products 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
NanoTechnology Tools continued 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
Magnetic Resonance business for quality assurance analysis 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
for the full year 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
Total cash spent on R&D during the year      30.3 28.3 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
Group, including financial, operational and 
• financial executives within Group 
Activities of the Audit and Risk Committee in respect of the financial year ended 31 March 2017
Awards were made to the Executive Directors for the 2016/17 year under the 2014 Performance Share Plan.
Maximum    12% per annum and above over three years 100% 72 Oxford Instruments plc Report and Financial Statements 2017
During the year, the Company contributed £7,478 (2016: £11,786) into the Company’s Group Personal Pension Plan in respect of Ian Barkshire 
• annual bonus for the financial year ended 31 March 2016 determined in accordance with the financial and non‑financial performance targets 
3. The value of the average employee bonus for the year ended 31 March 2017 (to be paid at the end of June 2017) was not known at the time the Report and Financial Statements 
the Group during the financial year ended 
• for the Group financial statements, state 
We have audited the financial statements of Oxford Instruments plc for the year ended 
company’s affairs as at 31 March 2017 and of the group’s loss for the year then ended; 
• the group financial statements have been properly prepared in accordance with International 
Group total assets 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
Accounting Policies  01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
• Software 10 years 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
Cash and cash equivalents at end of the year      26.5 20.4 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
During the year the Group settled various claims totalling £0.4m relating to the disposal of its Omicron business in the prior year.
During the year the Group recognised an impairment of £8.0m relating to its equity accounted associate investment.
Accordingly, the Group accounts for these derivative financial instruments at fair value through profit or loss.
The Group’s internal management structure and financial reporting systems differentiate the three aggregated operating segments on the basis of 
• the Industrial Products segment contains a group of businesses supplying high technology products and components manufactured in medium 
presented in reporting to the Group’s Board of Directors.
The adjusted loss after tax of £0.8m (2016: £0.2m) from the Group’s associate is reported within the NanoTechnology Tools segment.
In the prior year, a £0.6m impairment of capitalised development costs was included within administration and shared services in the Consolidated 
the accounting policies of the acquired business with the Group accounting policies and to reflect the fair value of assets and liabilities acquired.
• settled various claims totalling £0.4m relating to the disposal of its Omicron business in the prior year.; and
The Group’s share of loss in its equity accounted associate for the year was £1.2m (2016: £1.5m).
During the year the Group recognised an impairment charge of £8.0m relating to its investment in ScientaOmicron due to the associate’s financial 
Profit from discontinued operations after tax      5.0 2.2 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
The average number of people employed by the Group (including Directors and temporary employees) during the year was as follows:
The following dividends per share were proposed by the Group in respect of each accounting year presented:
During the year the Group made impairments in respect of intangible assets as follows:
During the year the financial performance of the Group’s Asylum CGU deteriorated with the business performing below expectations.
The financial performance of the Group’s Healthcare business also deteriorated in the US during the year, with business operating profit falling 
The £2.2m impairment of software costs represents inefficient capitalised costs relating to the Group’s new ERP system and has been reported as 
Net assets/(liabilities)    26.0 19.0 (5.6) (5.7) 20.4 13.3 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
Such instruments are only used to manage the risks arising from operating or financial assets or liabilities or highly probable future transactions.
The Group’s translational exposures to foreign currency risks can relate both to the Consolidated Statement of Income and net assets of overseas 
The Group is exposed to credit risk on financial assets such as cash 
amount of each financial asset, including derivative financial instruments, in the Group Consolidated Statement of Financial Position.
As set out in the Chief Executive’s Statement, the Group will actively manage its portfolio of businesses and products, selecting those markets 
Fair value of plan assets at the end of the year  282.5 5.4 287.9 235.0 4.5 239.5 118 Oxford Instruments plc Report and Financial Statements 2017
The Group expects to contribute approximately £7.6m to defined benefit plans in the next financial year.
Balance at 31 March 2017        — 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
During the year ended 31 March 2017, £4.5m was recognised as an expense in the Consolidated Statement of Income in respect of operating 
Details of issued, authorised and allotted share capital are included in Note 24 to the Group Financial Statements.
Details of the Group’s share option schemes are included in Note 13 to the Group Financial Statements.
Details of the Group’s defined benefit pension scheme are included in Note 26 to the Group Financial Statements.
year ended 31 March 2017 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
year ended 31 March 2017 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information
Oxford Instruments Directory 01: Strategic Report 02: Governance 03: Financial Statements 04: Company Information